西藏藥業(600211.SH):子公司獲得藥品補充申請批准通知書
格隆匯5月16日丨西藏藥業(600211.SH)公佈,本公司全資子公司成都諾迪康生物製藥有限公司於近日收到國家藥品監督管理局頒發的《藥品補充申請批准通知書》,新活素作為治療急性心衰的基因工程藥物,能快速改善心衰患者的心衰症狀和體徵,提高患者的生存質量。該產品為國家生物製品一類新藥,適用於患有休息或輕微活動時呼吸困難的急性失代償心力衰竭患者的靜脈治療,按NYHA分級>II級。
本次新活素凍幹生產線(凍幹車間B線)獲得上述《藥品補充申請批准通知書》,表明該生產線可以正式投入生產,公司新活素年產能將達到1500萬支,進一步提升了新活素生產能力,為公司發展奠定了基礎。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.